Key Highlights
- CONNEQT Health (ASX:CQT) reported a signed amendment expanding its US trial Supply contract from 30 to 45 sites.
- The amendment adds about USD 240,000, lifting the disclosed total contract value to approximately USD 950,000.
- The supplier will provide 15 additional SphygmoCor XCEL systems and 30 additional Oscar 2 ABPM systems.
- A 30% initiation fee on the amendment value is payable on execution, with ongoing charges invoiced monthly.
CONNEQT Health (ASX:CQT) develops and supplies vascular health technology. On 9 November 2026, it reported that Wholly Owned Subsidiary ATCOR Medical had signed an amendment to a US Phase 2b trial contract. The change covers additional study sites, more equipment and associated services for a privately owned US biopharmaceutical customer.
What changed in the trial supply contract?
The amendment expanded the contract from 30 to 45 investigational sites across the United States. CONNEQT linked the expanded scope to a second study visit added to the trial protocol. The customer is developing therapies in hypertension and other serious cardiovascular diseases. CONNEQT’s role under the described agreement is to supply leased monitoring systems and services for the study through its subsidiary. The November update refers to the original equipment and services agreement announced on 28 October 2025. It reports the scope agreed in the amendment.
In its October 2025 announcement, the company identified 30 SphygmoCor XCEL systems and 60 Oscar 2 ABPM systems for the original 30-site contract. The original scope also included set-up, training, support and data management for the participating sites. The 2025 disclosure described equipment and support for the collection of trial data. The amended quantities increase the number of systems of both types to be supplied under the contract.
Additional systems, Lease term and services
The company will supply 15 additional SphygmoCor XCEL systems and 30 additional Oscar 2 ABPM systems. The incremental equipment is to be leased for about seven months. The amendment also covers configuration of the devices, virtual operator Training and certification, continuing technical support and data management services. These services are included in the announced incremental contract value alongside leasing. The company said the number of sites and the additional visit expand the scope of the existing agreement with the same customer.
Contract value, billing and Revenue timing
CONNEQT reported incremental contract value of about USD 240,000, equivalent to approximately AUD 340,000. It gave the revised aggregate as approximately USD 950,000, or AUD 1.36 million, and described the increase as 33% against the original contract value of approximately USD 720,000. The US dollar amounts are rounded as reported. A non-refundable initiation fee equal to 30% of the amendment value is payable when the amendment is executed. Equipment lease and other continuing charges are invoiced monthly. The company said it expects to recognise revenue progressively over the trial.
Terms carried forward from the original agreement
CONNEQT reported that the amendment left unit pricing and other provisions under the original contract in place. It specifically identified confidentiality and termination terms among those continuing under the amended arrangement. Its disclosure gives the duration of the additional equipment lease and the schedule for invoicing ongoing charges. The overall dollar value describes contracted equipment and services over the agreement’s duration.
The company’s vascular health products include medical devices, home health devices and digital tools. The trial supply arrangement specifically concerns equipment and services for the sponsor’s Phase 2b study, including operator preparation at the participating US clinical trial sites.
The amendment places more equipment and support under the existing US contract. CONNEQT disclosed the value of that expanded supply arrangement and the timing for billing and revenue recognition as the work is delivered.






Please wait processing your request...